This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q78.3 (progressive diaphyseal dysplasia) | Special Copayment Reduction: V266 (rare disease) |
| B. Synonyms | Camurati-Engelmann syndrome | Progressive diaphyseal dysplasia |
| C. Adult onset | Likelihood of first onset in adulthood: moderate to high — symptom onset is most common in childhood to adolescence, but mild symptoms are often first recognized only in adulthood; because the clinical spectrum is broad, asymptomatic adults are sometimes found incidentally during family testing; cranial nerve complications can progress even in adulthood. |
| 1. History | 1920 first described by Cockayne → 1922 familial cases by Camurati (Italy) → 1929 clinical·radiological description established by Engelmann → 2000 TGFB1 gain-of-function mutations identified by Kinoshita et al. → developed into research on TGF-β signaling inhibition therapy. |
| 2. Causes | Gain-of-function mutations of the TGFB1 gene (19q13.2). Mutations in the latency-associated peptide (LAP) of TGF-β1 or the mature cytokine domain → excessive activation of TGF-β1 → hyperproliferation of osteoblasts·fibroblasts → progressive cortical thickening of the diaphyses of long bones. Autosomal dominant inheritance with variable penetrance. |
| 3. Genetics | TGFB1: 19q13.2, autosomal dominant (AD), incomplete penetrance. Main variants: R218H, R218C, Y81H, C225R, C225S, etc. (LAP domain variants most common). New mutations not uncommon. Partial genotype-phenotype correlation. Variable expression within families. |
| 4. General epidemiology | Prevalence about 1/1,000,000 (estimated). Only about 300 cases reported in the literature worldwide. Independent of sex·ethnicity. Broad onset from childhood to adulthood. Korean cases rarely reported. So rare that diagnostic delay is common. |
| 5. Pathophysiology | TGFB1 mutation → destabilization of the latent TGF-β1 complex → excessive release·activation of TGF-β1 → Smad2/3 phosphorylation → hyperactive proliferation of osteoblasts·fibroblasts → endosteal·periosteal thickening of diaphyseal cortical bone, narrowing of the medullary cavity. Imbalance of bone remodeling (bone formation >> bone resorption). Accompanied by muscle atrophy·nerve compression. |
| 6. Symptoms | Limb pain·fatigue (especially thighs·tibiae), waddling gait, muscle weakness, headache, cranial nerve palsies (loss of vision·hearing, facial palsy), raised intracranial pressure, spinal pain. Systemic: weight loss, fatigue, anemia. High symptom variability. |
| 7. Signs | X-ray·CT: symmetric cortical thickening of long bone diaphyses (endosteal·periosteal), narrowing of the medullary cavity, sclerosis of the skull base. 99mTc bone scan: increased diaphyseal uptake. ESR·CRP elevated. ALP elevated. Electromyography: myopathic findings. MRI: assessment of muscle·nerve involvement. |
| 8. Screening | In cases with a family history, clinical evaluation + limb·skull X-rays. Imaging abnormalities can be identified even in asymptomatic family members (incomplete penetrance). Confirmed by TGFB1 gene testing. When cranial nerve symptoms appear, nerve compression assessed by MRI·CT. Baseline ALP·ESR·CBC measured. |
| 9. Diagnosis | Three clinical elements: ① cortical thickening of long bone diaphyses (X-ray·CT), ② characteristic symptoms (limb pain·gait abnormality·cranial nerve symptoms), ③ family history or TGFB1 mutation. Differential: Ribbing disease, osteopetrosis, Paget disease, metastatic cancer. Confirmed by NGS TGFB1 gene analysis. Bone scan·MRI·endocrine evaluation. |
| 10. Treatment | Corticosteroids (prednisolone) are the main drug treatment — suppress pain·inflammation, partially suppress bone progression. Losartan (AT1R blocker) used in combination or alone via a TGF-β signaling inhibition mechanism. NSAIDs for pain (caution). Cranial nerve decompression. Rehabilitation·physical therapy. Vitamin D·calcium supplementation. |
| 11. Prognosis | Life expectancy generally close to normal. Limb pain·gait abnormality can be controlled with corticosteroids, but cure is difficult. Cranial nerve complications (blindness·hearing loss) greatly reduce quality of life and may become permanent. Symptom severity variable. Long-term follow-up needed. |
| 12. Prevention | Genetic counseling·prenatal diagnosis available (AD inheritance). Early recognition of symptoms and start of treatment to prevent cranial nerve complications. Regular ophthalmologic·hearing tests. Early start of corticosteroids to suppress bone progression. New TGF-β inhibitors under study. |
| 13. References | Janssens K, Vanhoenacker F, Bonduelle M, et al. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data ... and 9 other papers |
The history of progressive diaphyseal dysplasia (PDD) — now commonly called Camurati-Engelmann disease (CED) — begins in the European medical literature of the early 20th century. In 1920, Edward Alfred Cockayne of England first described a patient showing sclerosis and thickening of the diaphyses of the long bones. Mario Camurati of Italy reported familial cases in 1922, pointing out the hereditary tendency of the disease. Guido Engelmann of Germany described in detail in 1929 the clinical features and radiological findings of progressive cortical thickening and medullary cavity narrowing of the long bone diaphyses, contributing to a systematic definition of the disease. The disease was later named 'Camurati-Engelmann disease' after the two physicians.
In the mid-20th century, sporadic cases were reported from several centers around the world, and the autosomal dominant inheritance pattern was established. The diversity of clinical symptoms and incomplete penetrance within families were recognized as factors making clinical diagnosis difficult. In the 1990s, linkage analysis narrowed the location of the causative gene to the long arm of chromosome 19 (19q13). In 2000, Kinoshita et al. of Japan first reported that gain-of-function mutations of the TGFB1 gene cause CED, and in the same year Janssens et al. identified mutations in the same gene in Belgian families. Identification of TGFB1 mutations offered a new direction for understanding the pathophysiology and developing treatments.
In the history of treatment, it has been clinically observed since the 1960s that corticosteroids (mainly prednisolone) are effective in improving limb pain and gait abnormalities, and they are still used as first-line drug treatment. In the 2010s, case reports and small studies were published showing that losartan, an angiotensin II receptor blocker (ARB) that indirectly blocks the TGF-β signaling pathway, reduced pain and suppressed bone progression in CED patients. Recently, direct TGF-β-neutralizing antibodies, small-molecule Smad signaling inhibitors, and others are in preclinical research, and future treatment advances are expected. In Korea, registration for rare disease Special Copayment Reduction (V266) is also possible, and case reports are gradually increasing.
The cause of progressive diaphyseal dysplasia (Camurati-Engelmann disease) is a gain-of-function mutation of the TGFB1 gene (19q13.2). TGFB1 encodes transforming growth factor β1 (TGF-β1), a multifunctional cytokine broadly involved in bone metabolism, immune regulation, tissue fibrosis, and angiogenesis.
Normal TGF-β1 forms a noncovalent bond with the latency-associated peptide (LAP) and is secreted as a latent complex (small latent TGF-β1 complex); it remains bound to the extracellular matrix until active TGF-β1 is released by proteases, integrins, heat, reactive oxygen species, etc. Mutations causing CED are mainly located in the LAP domain (exon 4), and the most common variants are R218H (Arg218His), R218C (Arg218Cys), Y81H, C225R, and C225S. These variants weaken the noncovalent bond between LAP and mature TGF-β1, so the latent complex readily dissociates and excess active TGF-β1 is released. As a result, TGF-β1 signaling is maintained abnormally high and persistent.
TGFB1 mutations are inherited in an autosomal dominant manner, and because penetrance is incomplete, symptomatic members, members with only imaging abnormalities, and asymptomatic members coexist even within the same family. New mutations (de novo) are also reported not infrequently. The causes of variable penetrance and phenotypic diversity are explained by genetic background (modifier genes), environmental factors, and individual differences in TGF-β signaling responsiveness.
Rarely, clinical CED-like cases without an identified TGFB1 mutation are also reported, which may be due to other genetic causes (TGFB1 noncoding variants, variants in other TGF-β pathway genes). Even if genetic testing is negative, a clinical diagnosis is possible if clinical·radiological findings are typical.
The TGFB1 gene is located on the long arm of chromosome 19 (19q13.2) and consists of 7 exons. The encoded TGF-β1 precursor protein (pre-pro-protein) consists of an N-terminal signal peptide, the latency-associated peptide (LAP, pro domain), and the mature TGF-β1 domain. CED-related mutations are concentrated mainly in the LAP domain of exon 4. R218 is a key residue of the cysteine bonding network involved in disulfide bonds within the LAP domain, and mutations at this position destabilize the LAP structure, promoting spontaneous release of mature TGF-β1.
The genotype-phenotype correlation is incomplete. Even within families carrying the same variant (e.g., R218H), clinical presentation ranges from adults with mild symptoms to patients with severe limb pain·gait abnormality in childhood. This reflects variable penetrance of TGFB1 variants and individual differences in the ability to regulate TGF-β1 signaling. Some studies report that the Y81H variant is associated with a milder phenotype than the R218H variant, but large cohort data are lacking.
Molecular diagnosis is performed by Sanger sequencing or an NGS panel analyzing TGFB1 exons 1-7 (especially exon 4). When a mutation is found, family testing to confirm AD inheritance, planning of prenatal diagnosis (CVS or amniocentesis), and genetic counseling are carried out. Pathogenicity is assessed with reference to CED-related variants reported in TGFB1 variant databases (ClinVar, HGMD).
Progressive diaphyseal dysplasia (Camurati-Engelmann disease) is a very rare disease worldwide; its prevalence is estimated at about 1/1,000,000, but the actual prevalence is uncertain owing to diagnostic delay and undiagnosed cases. Through the 2020s, only about 300 cases have been reported in the literature worldwide. It occurs regardless of sex·ethnicity, and cases have been reported from various regions, including Europe·North America·Asia·the Middle East.
Both familial and sporadic cases are reported, and in familial cases autosomal dominant inheritance over 3–4 generations is confirmed. Sporadic cases include those due to new mutations or incomplete penetrance. The age at clinical onset ranges widely from childhood (5–10 years) to adulthood, and mild forms are sometimes not diagnosed until adulthood.
In Korea it is registered as a disease eligible for rare disease Special Copayment Reduction (V266), and domestic case reports are few. A small number of familial cases have also been reported in Japan, including East Asian cases with confirmed TGFB1 gene mutations. Diagnostic delay is common, and patients are often misdiagnosed with other conditions for years after symptom onset, so raising clinician awareness is important.
The core pathophysiology of Camurati-Engelmann disease is overactivation of the TGF-β1 signaling pathway due to TGFB1 gain-of-function mutations and the resulting progressive thickening of diaphyseal cortical bone.
In normal bone homeostasis, TGF-β1 plays a dual role in the bone remodeling cycle. During bone resorption by osteoclasts, TGF-β1 stored in the bone matrix is activated and released, and this TGF-β1 acts as a 'coupling factor' that promotes migration and early differentiation of osteoblast precursors from bone marrow stromal cells. At the same time, TGF-β1 inhibits late osteoblast maturation and mineralization, acting as a coordinator of bone formation. In CED, TGF-β1 that is overactivated owing to LAP mutations continuously activates intracellular signaling through Smad2/3 phosphorylation.
Excess TGF-β1 signaling promotes proliferation·activation of osteoblast precursors and fibroblasts, so that bone deposition increases on both the endosteal and periosteal sides of the diaphyseal cortical bone. Thickening on the endosteal side causes narrowing of the medullary cavity, and thickening on the periosteal side appears as increased diaphyseal thickness. In this process, normal bone remodeling is suppressed, and abnormal cortical bone forms in which immature woven bone and fibrous matrix are mixed, rather than mature lamellar bone.
In muscle, TGF-β1 promotes muscle fiber atrophy and fibrosis, causing muscle weakness and a waddling gait. In the skull and skull base, excessive bone deposition narrows the foramina through which cranial nerves pass, causing cranial nerve palsies of the optic, acoustic, facial, and other nerves. In blood vessels, excess TGF-β1 can cause vessel wall fibrosis and intimal proliferation, which can impair limb blood flow. In addition, TGF-β1 is a potent immunomodulatory factor, and in excess the systemic inflammatory response is activated, producing anemia, weight loss, and fatigue.
The clinical symptoms of Camurati-Engelmann disease are highly variable, and even within families carrying the same TGFB1 variant, the presence and severity of symptoms differ greatly. The most common and characteristic symptoms are limb pain and gait abnormality.
Limb pain: Deep pain in the thighs·shins is the most common symptom, worsening with activity and easing with rest. The location of pain varies along the length of the legs, and night pain is prominent. In pediatric patients it may be mistaken for growing pains. The upper limbs (upper arms) can also be involved, but less often than the lower limbs.
Gait abnormality (waddling gait): A combination of proximal muscle weakness and bone deformity produces a characteristic waddling gait. This is due to atrophy and fibrosis caused by excess TGF-β1 in the pelvic·proximal thigh muscles. In severe cases, wheelchair use may be required.
Cranial nerve symptoms: Bone deposition in the skull base and skull narrows the cranial nerve foramina, causing reduced vision or blindness (optic nerve compression), hearing loss (acoustic nerve compression, conductive or sensorineural), and facial palsy (facial nerve compression). Headache may accompany raised intracranial pressure, and facial pain sometimes appears due to trigeminal nerve compression.
Systemic symptoms: Symptoms due to systemic TGF-β1 excess, such as weight loss, fatigue, generalized weakness, and anorexia, may be present. Anemia is due to reduced hematopoiesis from medullary cavity narrowing or to chronic inflammation. Hepatosplenomegaly is rarely reported.
Spinal symptoms: Spinal involvement may cause spinal pain and nerve compression symptoms due to spinal canal stenosis (radiating pain, lower-extremity weakness). If basilar invagination progresses, cerebellar·brainstem symptoms develop.
The physical, radiological, and laboratory signs of Camurati-Engelmann disease are characteristic, as follows.
Radiological signs: On plain X-ray, symmetric cortical thickening of the diaphyses of long bones is most characteristic. The femur, tibia, fibula, humerus, radius, and ulna are mainly involved. Thickening appears on both the endosteal and periosteal surfaces of the diaphyseal cortex, and narrowing of the medullary cavity is observed. Sclerotic findings also appear in the skull base and calvaria. The spine and pelvis may also be involved. The epiphyses and metaphyses are generally spared.
Nuclear medicine imaging: On 99mTc whole-body bone scan, markedly increased radioisotope uptake appears in the involved diaphyses. This reflects active bone deposition, and decreased uptake after treatment is used as an indicator of response.
Laboratory findings: Serum alkaline phosphatase (ALP) is elevated (reflecting increased bone formation turnover), and the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are also elevated. Mild anemia (normocytic normochromic anemia) is observed in some patients. Bone metabolism markers (P1NP, CTX) may be elevated. Elevated serum TGF-β1 levels have been reported in some studies, but diagnostic specificity is low.
Electromyography/nerve conduction studies: In patients with muscle weakness, myopathic findings (short-duration, low-amplitude polyphasic motor unit potentials) may be observed on electromyography.
MRI: In addition to diaphyseal cortical thickening, atrophy·fibrosis of the surrounding muscles and findings of nerve compression are assessed. Skull base MRI determines the degree of cranial nerve compression and whether the brainstem·cerebellum are involved. Hydrocephalus and cerebellar atrophy are rarely observed on brain MRI.
Universal screening of the general population for Camurati-Engelmann disease is not performed. Systematic evaluation is carried out when there is a family history or when the disease is clinically suspected.
When there is a family history: Because inheritance is AD, the variant may be transmitted to 50% of the children of an affected parent. If a TGFB1 variant has been identified in the family, genetic testing of children and other family members determines carrier and affected status. When a gene variant is confirmed, radiological evaluation (limb·skull X-rays) is performed even without clinical symptoms to check for asymptomatic diaphyseal lesions. Because penetrance is incomplete, asymptomatic variant carriers also need regular follow-up.
Criteria for clinical suspicion: CED is suspected in the following situations. ① Deep pain in the limbs (especially thighs·tibiae), gait abnormality, and muscle weakness persisting for years in children·adolescents·adults; ② symmetric cortical thickening of long bone diaphyses on radiographs; ③ cranial nerve symptoms (visual·hearing abnormalities, facial palsy) combined with bone abnormalities; ④ family history (parent or sibling with similar symptoms).
Baseline tests: At the start of diagnostic evaluation, serum ALP, ESR/CRP, CBC, serum calcium·phosphorus, 25-OH vitamin D, and PTH are measured to establish baseline values and to differentiate from other metabolic bone diseases. A whole-body bone scan gives an overall picture of the involved sites.
Genetic testing: If clinical·imaging findings are consistent with CED, TGFB1 gene analysis (priority analysis of exon 4 or whole-gene NGS) is performed to confirm the diagnosis. If a variant is found, family testing is extended.
Diagnosis of Camurati-Engelmann disease is made by integrating clinical findings, radiological imaging, and molecular genetic analysis. In typical cases, diagnosis is made when three elements are met — ① cortical thickening of long bone diaphyses (X-ray), ② characteristic clinical symptoms (limb pain·gait abnormality·cranial nerve abnormality), ③ TGFB1 mutation or family history.
Radiological imaging evaluation: On X-rays of long bones (femur·tibia·humerus, etc.), symmetric endosteal·periosteal thickening of the diaphyseal cortex and narrowing of the medullary cavity are characteristic. CT of the skull·facial bones·skull base assesses the degree of narrowing of the cranial nerve canals. A 99mTc whole-body bone scan gives an overall picture of sites of active bone deposition. MRI is used to assess muscle involvement, nerve compression, and intracranial abnormalities.
Differential diagnosis: Diseases with similar radiological findings include ① Ribbing disease (adult diaphyseal sclerosis) — debated as a mild form of CED or a separate disease; ② osteopetrosis — generalized increase in bone density, osteoclast defect; ③ Paget disease — adult onset, markedly elevated ALP; ④ metastatic bone disease — unilateral, different nuclear medicine findings; ⑤ chronic osteomyelitis — accompanying signs of infection, etc. TGFB1 gene analysis is decisive for final differentiation from these.
Molecular genetic confirmation: A pathogenic variant is identified by Sanger analysis or an NGS panel of the TGFB1 gene. Because exon 4 (LAP domain) is the most common variant location, it is analyzed first. If no variant is found, full TGFB1 gene analysis, RNA analysis, and functional testing are considered. ClinVar·HGMD·ACMG criteria are applied for pathogenicity assessment.
Endocrine and metabolic evaluation: Serum ALP, calcium, phosphorus, PTH, 25-OH vitamin D, serum TGF-β1 (for research purposes), P1NP, CTX, CBC, and liver function tests are performed. ALP is used as an indicator for monitoring treatment response.
Ophthalmologic·audiologic evaluation: To assess cranial nerve involvement, visual acuity·visual field·fundus·visual evoked potential (VEP) tests and pure-tone audiometry·ABR are performed regularly. If optic nerve compression is suspected, immediate MRI/CT and ophthalmology consultation are needed.
Treatment of Camurati-Engelmann disease mainly aims at symptom management, and there is as yet no curative treatment. Corticosteroids are the main treatment, and losartan is used as a drug with a new mechanism.
Corticosteroids: Prednisolone (0.5–1 mg/kg/day or alternate-day dosing) is the most widely used drug. Its mechanism of action is suppression of TGF-β1 production and an anti-inflammatory effect, and numerous case reports have confirmed it to be effective in reducing limb pain and improving gait. Decreased uptake on bone scan and normalization of serum ALP are also observed. With long-term administration, monitoring and management of steroid adverse effects such as adrenocortical insufficiency, osteoporosis, growth suppression (children), increased susceptibility to infection, and metabolic abnormalities are needed. Alternate-day dosing is preferred as a way to reduce adverse effects while maintaining efficacy. The minimum effective dose is found and maintained long term.
Losartan: An angiotensin II type 1 receptor blocker (AT1R blocker, ARB) known to indirectly inhibit TGF-β1 signaling in addition to controlling blood pressure. After a TGF-β1-inhibiting effect was reported in Marfan syndrome, its application to CED was attempted. Small studies and case reports have reported reduced pain, improved muscle strength, and improvement on bone scan. It can be used alone or in combination with corticosteroids and is considered as an alternative in patients in whom corticosteroid adverse effects are a concern. Monitoring for hypotension, renal dysfunction, and electrolyte imbalance is needed.
Pain management: NSAIDs (nonsteroidal anti-inflammatory drugs) are used for pain management, but caution is needed regarding gastrointestinal adverse effects and nephrotoxicity. Acetaminophen can be used as a first-choice agent for moderate pain. When there is a neuropathic pain component, gabapentin or pregabalin may help.
Cranial nerve decompression: Surgical decompression is considered when cranial nerve compression progresses owing to narrowing of the optic canal·acoustic canal·facial nerve foramen. Deciding the timing of surgery is difficult, and damage that has already progressed is difficult to recover fully. The decision is made through a multidisciplinary approach at a specialized neurosurgical center.
Rehabilitation and physical therapy: Muscle-strengthening exercise (low-impact exercise, aquatic therapy), gait training, and prescription of assistive devices (cane, walker) are important for maintaining function. When there is spinal pain, core muscle strengthening and posture correction therapy are performed.
Vitamin D and calcium: Supplementation is recommended when vitamin D deficiency is present, and adequate calcium intake is maintained. Considering the pathophysiology of excessive bone formation in CED, bisphosphonates require caution and are not used as standard treatment.
The prognosis of Camurati-Engelmann disease varies greatly from patient to patient because the clinical spectrum is broad. Overall, life expectancy is close to normal, but cranial nerve complications and limb pain·gait abnormality greatly reduce quality of life.
Skeletal and functional prognosis: Limb pain and gait abnormality can improve considerably with corticosteroid treatment. In patients who respond to treatment, reduced pain scores, improved gait function, and reduced bone scan activity are seen. However, symptoms often recur when treatment is stopped, so long-term treatment is needed. Diaphyseal cortical thickening often does not clearly improve radiologically even after treatment, and improvement of clinical symptoms tends to precede imaging improvement.
Cranial nerve complications: Vision loss due to optic nerve compression and hearing loss due to acoustic nerve compression can be permanent when advanced and have the greatest impact on prognosis. Early detection and treatment (corticosteroids or surgical decompression) are important for minimizing nerve damage. Hearing loss can be partly compensated with hearing aids.
Natural course and long-term follow-up: In some patients, a natural course in which symptoms stabilize or improve after adulthood has been reported, but most require ongoing monitoring and treatment. In long-term follow-up, new onset or progression of cranial nerve complications can also occur in adults, so lifelong follow-up is needed. Treatment response is assessed every 3–6 months through symptom assessment, ALP·ESR, bone scan, and ophthalmologic·audiologic tests.
Prevention of the occurrence of Camurati-Engelmann disease itself is possible only through genetic counseling and preimplantation·prenatal diagnosis. Clinically important prevention is preservation of function through early detection and treatment of complications.
Genetic counseling and prenatal diagnosis: When a TGFB1 mutation has been identified in the family, because inheritance is AD, the variant is transmitted to 50% of the children of an affected parent. When planning pregnancy, whether the fetus is affected can be determined by preimplantation genetic testing (PGT-M) or prenatal diagnosis (CVS or amniocentesis). Genetic counseling must explain that, because penetrance is incomplete, variant carriers do not necessarily show symptoms.
Early diagnosis and start of treatment: Early diagnosis and starting corticosteroid treatment before cranial nerve complications (vision·hearing loss) progress to irreversible damage is key to preserving function. If there is a CED patient in the family, other family members undergo regular evaluation (X-ray, ALP, ophthalmology, hearing).
Regular monitoring: Ophthalmologic examination (visual acuity·visual field·fundus, visual evoked potentials) and hearing tests are performed every 6–12 months to detect cranial nerve compression complications early. ALP and ESR/CRP are measured regularly to assess disease activity and treatment response. Bone scans are performed every 1–2 years to track lesion progression.
Lifestyle guidance: Adequate intake of calcium (age-specific recommended amount) and vitamin D (serum 30 ng/mL or higher) is maintained. Muscle strength is maintained with regular low-impact exercise (swimming, cycling), and high-intensity exercise that worsens pain is limited. In patients on long-term corticosteroids, regular bone density assessment by dual-energy X-ray absorptiometry (DXA) and prevention of secondary osteoporosis are needed.
Janssens K, Vanhoenacker F, Bonduelle M, et al. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet. 2006;43(1):1-11. DOI: 10.1136/jmg.2005.033522. PMID: 15879500.
Kinoshita A, Saito T, Tomita H, et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet. 2000;26(1):19-20. DOI: 10.1038/79128. PMID: 10973241.
Janssens K, ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-β1 to the bone. Endocr Rev. 2005;26(6):743-774. DOI: 10.1210/er.2004-0001. PMID: 15901665.
Verbruggen LA, Bossuyt A, Schreuer R, et al. Treatment with losartan in Camurati-Engelmann disease: a case report. Clin Rheumatol. 2013;32(3):405-409. DOI: 10.1007/s10067-012-2120-7. PMID: 23109088.
Inaoka T, Shuke N, Sato J, et al. Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease). Clin Nucl Med. 2001;26(8):680-682. DOI: 10.1097/00003072-200108000-00008. PMID: 11452192.
Kaftori JK, Kleinhaus U, Naveh Y. Progressive diaphyseal dysplasia (Engelmann's disease): treatment with corticosteroids. J Bone Joint Surg Am. 1987;69(1):129-131. PMID: 3805082.
Makita N, Suzuki M, Asami S, et al. Two of four mutations identified in camurati-Engelmann disease alter TGF-β1 bioavailability through mechanisms involving disulfide bonding to the latent TGF-β1-binding protein. J Biol Chem. 2000;275(15):11026-11032. DOI: 10.1074/jbc.275.15.11026. PMID: 10753904.
De Matteis G, Capacci G, Capobianco M, et al. Use of losartan in Camurati-Engelmann disease: a new therapeutic option. J Endocrinol Invest. 2015;38(4):481-485. DOI: 10.1007/s40618-014-0203-7. PMID: 25391433.
Van Hul W, Boudin E, Vanhoenacker FM, Mortier G. Camurati-Engelmann disease. Calcif Tissue Int. 2019;104(5):554-560. DOI: 10.1007/s00223-019-00526-7. PMID: 30637450.
Fatima N, Alsaad SK. Progressive diaphyseal dysplasia presenting as intracranial hypertension. BMJ Case Rep. 2019;12(10):e230945. DOI: 10.1136/bcr-2019-230945. PMID: 31601603.